Jove
Visualize
Contact Us

Related Experiment Videos

Ophthalmic disodium cromoglycate.

D W Tierney

    Journal of the American Optometric Association
    |December 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Disodium cromoglycate is now approved for eye conditions like allergic conjunctivitis. This mast cell inhibitor offers therapeutic benefits for IgE-mediated conjunctivitis, balancing efficacy with side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    An evaluation of self-report measures of cognitive distortions and empathy among Australian sex offenders.

    Archives of sexual behavior·2001
    Same author

    Ocular manifestations of syphilis.

    Journal of the American Optometric Association·1989
    Same author

    Vision recovery in amblyopia after contralateral subretinal hemorrhage.

    Journal of the American Optometric Association·1989
    Same author

    Ocular chrysiasis.

    Journal of the American Optometric Association·1988
    Same author

    Visual dysfunction in closed head injury.

    Journal of the American Optometric Association·1988
    Same author

    Betaxolol and levobunolol: new beta-blocking antiglaucoma agents.

    Journal of the American Optometric Association·1987
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Ophthalmology
    • Allergology
    • Pharmacology

    Background:

    • Conjunctivitis, particularly IgE-mediated forms, presents a significant clinical challenge.
    • Disodium cromoglycate, a mast cell stabilizer, has gained recent FDA approval for ophthalmic use.
    • Understanding its role in treating specific conjunctivitis types is crucial for patient management.

    Purpose of the Study:

    • To review the therapeutic efficacy and clinical benefits of disodium cromoglycate in treating IgE-mediated conjunctivitis.
    • To evaluate the side effect profile of disodium cromoglycate in ophthalmic applications.
    • To provide a foundation for understanding the risk-benefit balance of this treatment.

    Main Methods:

    • Literature review of studies on disodium cromoglycate for conjunctivitis.

    Related Experiment Videos

  • Analysis of clinical trial data and case reports.
  • Assessment of efficacy in vernal keratoconjunctivitis, allergic conjunctivitis, chronic conjunctivitis, and giant papillary conjunctivitis.

    • Main Results:

    • Disodium cromoglycate demonstrates effectiveness in treating various forms of conjunctivitis, especially in patients with atopic history or low IgE levels.
    • The drug acts as a mast cell inhibitor, mitigating allergic inflammatory responses in the eye.
    • A favorable balance between therapeutic benefits and side effects is noted, supporting its clinical utility.

    Conclusions:

    • Disodium cromoglycate is a valuable therapeutic option for specific IgE-mediated conjunctivitis.
    • Its efficacy is enhanced in patients with underlying atopic conditions.
    • Further understanding of its long-term benefits and side effect management is supported by this review.